2017-08-31 14:40:59 UTC

A Look Back at the TREAT Registry

Aug. 31, 2017

CGH is reviewing the strides made in Crohn’s disease treatment.

Celebrating 15 years of publication, Clinical Gastroenterology and Hepatology (CGH) looks back and discusses a landmark article on the Crohn’s Therapy, Resource, Evaluation and Assessment Tool (TREAT) registry.

The TREAT registry, initiated July 1999, set out to answer questions on the long-term efficacy and safety in the medications being used in Crohn’s disease patients. Approximately 80 percent of the 6,273 patients were community based and 20 percent were based in academic institutions.

The large number of patients in the TREAT registry permitted multivariate analyses to isolate the effects of several medications, either used independently or as part of combination therapies. 

Lessons Learned from the TREAT Registry 

  • Risk and predictors of malignancy.
  • Serious infections and mortality in patients with Crohn’s disease.
  • Pregnancy-related risks of Crohn’s disease treatments.

Landmark articles were chosen by the CGH Board of Editors and represent discoveries that advanced the science and practice of gastroenterology.

More on Crohn's Disease

Crohn's & Colitis Congress™ (A Partnership of the Crohn's & Colitis Foundation and American Gastroenterological Association)

Jan. 18, 2018

Expand your knowledge, network with IBD leaders, spark innovative research and get inspired to improve patient care.

Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months

Oct. 22, 2017

We investigated whether serum trough levels of vedolizumab, during the induction phase can determine whether patients need additional doses within 6 months.

Healing of Tonsillar Crohn’s Disease With Infliximab

Oct. 22, 2017